Journal Information
Vol. 46. Issue S7.
Hematology Specialist Association 18. National Congress
Pages S43-S44 (December 2024)
Vol. 46. Issue S7.
Hematology Specialist Association 18. National Congress
Pages S43-S44 (December 2024)
PP 02
Full text access
AN AML CASE PRESENTING WITH EXTRAMEDULLARY MYELOID SARCOMA
Visits
290
Songül Beskisiz Dönen1,*, Vehbi Demircan1, Abdullah Karakuş1, Mehmet Orhan Ayyıldız1
1 Dicle University Faculty of Medicine, Department of Hematology
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (2)
Special issue
This article is part of special issue:
Vol. 46. Issue S7

Hematology Specialist Association 18. National Congress

More info
Objective

This case highlights an atypical presentation of myeloid sarcoma in a patient with acute myeloid leukemia (AML), focusing on diagnostic challenges, treatment decisions, and outcomes. The case emphasizes extramedullary involvement and therapeutic approaches for patients with poor performance status.

Case Report

A 68-year-old woman presented with neck swelling. Ultrasound and CT imaging revealed multiple enlarged cervical lymph nodes, with the largest measuring 30 × 25 mm in the right submandibular region. A tru-cut biopsy confirmed myeloid sarcoma infiltration. Upon admission, she was not cytopenic, but peripheral blood smear revealed blasts. Bone marrow biopsy confirmed AML, and diffuse chloroma foci were noted on her face. Due to poor performance status, the 5+1 chemotherapy regimen (5 days cytarabine, 1 day anthracycline) was initiated. After achieving remission in bone marrow, HDAC (high-dose cytarabine, 1500 mg/day) was administered as consolidation therapy. Severe cytopenias during HDAC led to a switch to azacitidine (Vidaza, 75 mg/m²) and venetoclax. Allogeneic stem cell transplantation (AlloSCT) was recommended, but the patient declined.

Conclusion

This case illustrates the diagnostic challenges of myeloid sarcoma in rare locations like the neck, compounded by diffuse chloroma. For patients with poor performance status, low-intensity regimens such as azacitidine and venetoclax are viable alternatives to intensive chemotherapy. AlloSCT remains the preferred treatment for high-risk AML, but in this case, azacitidine and venetoclax provided an alternative therapeutic pathway.

Full text is only available in PDF
Download PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Article options
Tools